Dr. Gitlitz on EGFR Exon 20 Insertion Mutations in Lung Cancer

Barbara J. Gitlitz, MD
Published: Friday, Aug 28, 2015

Barbara J. Gitlitz, MD, associate professor of Clinical Medicine, Keck Hospital of USC Norris Comprehensive Cancer Center, discusses treating patients with EGFR exon 20 insertion mutations in lung cancer.

 Exon 20 insertion mutations are the third most common type of EGFR mutation that patients with lung cancer present with, says Gitlitz. While this mutation will show up in a report as an EGFR mutation, it does not respond to any currently available EGFR inhibitors. It is important to be aware that a patient with an EGFR mutation has an exon 20 insertion, explains Gitlitz.

 Exon 20 insertion mutations are currently a target without a treatment, says Gitlitz. More clinical trials are needed.

Barbara J. Gitlitz, MD, associate professor of Clinical Medicine, Keck Hospital of USC Norris Comprehensive Cancer Center, discusses treating patients with EGFR exon 20 insertion mutations in lung cancer.

 Exon 20 insertion mutations are the third most common type of EGFR mutation that patients with lung cancer present with, says Gitlitz. While this mutation will show up in a report as an EGFR mutation, it does not respond to any currently available EGFR inhibitors. It is important to be aware that a patient with an EGFR mutation has an exon 20 insertion, explains Gitlitz.

 Exon 20 insertion mutations are currently a target without a treatment, says Gitlitz. More clinical trials are needed.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x